 Mirati Therapeutics Inc NASDAQ: MRTX has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose in pretreated patients with pancreatic ductal adenocarcinoma and other gastrointestinal GI tumors. As of September 10, 2021, the subset of patients with GI cancers harboring a KRASG12C mutation enrolled in the adagrasib monotherapy arm n30. 